Scale Alert: Aurion Biotech Hires CMO & CQO
Aurion Biotech just added a CMO & CQO. They need scalable CDMO networks and reg-automation to nail Phase 3. Execute your next touch now.
Published on
Do not index
Do not index
🚀 Battle Card
🚀 Battle Card: Aurion Biotech
Quick trigger:
👤 Decision Maker in the News
- Andrew Torres, Ph.D., Chief Manufacturing Officer · 🔗 [LinkedIn](https://www.linkedin.com/company/aurion-biotech/about/)
- Sterling Chung, Chief Regulatory & Quality Officer · 🔗 [LinkedIn](https://www.linkedin.com/company/aurion-biotech/about/)
💡 Why It Matters
- This Aurion Biotech sales trigger highlights the urgency to scale manufacturing and regulatory ecosystems ahead of the Phase 3 trial of AURN001 → Source
🎯 Core Pain Point
- Emerging cell therapy manufacturing processes lack scale and global compliance
- Complex multi-regional regulatory hurdles for novel cell therapies
💰 What to Pitch
- Primary: CDMO network integration → Scalable, compliant global manufacturing ready for Phase 3
- Expansion: Regulatory submission automation platform → Accelerated RMAT, BTD, and global approvals
🗺️ Quick Context
- HQ: Seattle, WA & Cambridge, MA & Tokyo
- Employees: ≈ 150
- Rev: ≈ $5 M
🤼 Competitive Intel
*Which other vendors you’ll probably face to win Aurion Biotech’s business.*
- Catalent — CDMO
- Unique edge: Proven global cell therapy scale-up
- Evaluated by CMOs & VP Ops for throughput
- Lonza — CDMO
- Unique edge: End-to-end mammalian GMP manufacturing
- Evaluated by Chief Manufacturing Officer for compliance track record
- WuXi AppTec — CDMO
- Unique edge: Integrated discovery-to-commercial services
- Evaluated by VP Ops for turnkey offerings
- Sartorius — Bioprocess equipment
- Unique edge: Modular single-use systems for scale
- Evaluated by Manufacturing teams for flexibility
- Veeva Systems — Regulatory/QMS
- Unique edge: Compliant cloud-based quality management
- Evaluated by Chief Regulatory & Quality Officer for audit readiness
✅ Do-Now Checklist
Connect with all decision makers on LinkedIn (links above)
Generate email + DM with the Copy-My-Prompt block (Step 7) and send first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Get the next Aurion Biotech sales trigger intel like this daily—no fluff, all pipeline.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑BioScaleCDMO❑
OFFER_BRIEF = ❑Scalable, compliant global cell therapy manufacturing network❑
PROOF_METRIC = ❑30% faster scale-up❑
CTA_STYLE = ❑quick_call❑
TONE = ❑punchy❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Andrew
COMPANY = Aurion Biotech
DEPT = Manufacturing
SIZE = ≈12
BOTTLENECK = lack of scalable cell therapy manufacturing
EVENT = promotion to Chief Manufacturing Officer
DETAIL = promotion to Chief Manufacturing Officer
PAIN = emerging processes lack global scale and compliance
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250930926770&div=41152219
SIM_CO = Catalent
WIN_METRIC = 30% faster scale-up
NEXT_SIZE = ≈30
EMP_EST = ≈150
REV_EST = ≈5M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈12-person Manufacturing
Andrew—noticed your Manufacturing team is ≈12.
That’s when lack of scalable cell therapy manufacturing slows growth.
We helped Catalent fix this with Scalable, compliant global cell therapy manufacturing network.
Result: 30% faster scale-up.
Quick call?
PS—next bottleneck hits ≈30.
DM ≤45 words, TONE:
Saw your post about promotion to Chief Manufacturing Officer — emerging processes lack global scale and compliance.
Scalable, compliant global cell therapy manufacturing network. 30% faster scale-up.
Quick chat?